[STUDY_ID_REMOVED] 
 
Study ID: 1839‐201‐021 
 
 
Title:  A Phase 2, Multicenter, Randomized, Double‐blind, Placebo‐contr olled, Single‐treatment, 2‐stage, 
Dose‐finding Study Evaluating the Efficacy and Safety of BOTOX®  Intravesical Instillation in Participants 
With Overactive Bladder and Urinary Incontinence 
 
Protocol Amendment 2 Date: 20Dec2018 
 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
Title Page 
Protocol Title: A Phase 2, Multicenter, Randomized , Double-blind, Placebo-controlled, 
Single-treatment, 2-stage, Dose-finding Study Evaluating the Efficacy and Safety of BOTOXﬁ 
Intravesical Instillation in Participants with Overactive Bladder and Urinary Incontinence 
Amendment Number: 2 
Brief Protocol Title: BOTOXﬁ Intravesical Instillation in Participants with Overactive Bladder 
and Urinary Incontinence 
Product: BOTOXﬁ (Botulinum Toxin Type A) Purified Neurotoxin Complex (US Adopted 
Name [CONTACT_687984]) 
Sponsor Name [CONTACT_29560]: Allergan (North America), [ADDRESS_1239385], 
Irvine, [LOCATION_004] [LOCATION_003], [ZIP_CODE] 
Regulatory Agency Identifying Number(s):  Investigational New Drug (IND) number 
Emergency Telephone Number: Refer to the study contacts page  
SAE Reporting Fax Number/Email:   
Business Unit 
/Legacy 
Organization Email Fax 
Allergan Pharmaceuticals 
Sponsor Signatory: 
Vice President and Therapeutic Area Head 
Internal Medicine, Womens Hea lth, Anti-Infectives and Urology 
Refer to the final page of this protocol fo r electronic signature [CONTACT_51472]. 
 
 
04DEC2020 Abbreviated CSR 1839-201-021
1

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
Protocol Amendment Summary of Changes Table 
 
Document History 
Document Date 
Amendment [ADDRESS_1239386] 2017 
Original Protocol 8 June 2017 
 
Amendment 2 (20 Dec 2018) 
 
Overall Rationale for the Amendment: 
Section Revision Summary 
Protocol Title Page Sponsor signatory changed Update due to change in 
sponsor signatory 
1. Synopsis Location of study sites changed from North America and Europe to North America and Canada Updated location of study  
6.2. Exclusion Criteria, 1.03 Implanted electrostimulation/ 
neuromodulation devices must be 
inactive 4 weeks prior to screening diary instead of randomization/Day 1 Clarified language to ensure 
no effects from the device 
are remaining during the diary completion period 
04DEC2020 Abbreviated CSR 1839-201-021
2

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
6.2. Exclusion Criteria, 1.07 Specified exclusionary PSA level 
limits are to be determined from 
screening lab results Clarified language 
6.2. Exclusion Criteria, 2.01  Defined therapi[INVESTIGATOR_014] as non- pharmacotherapi[INVESTIGATOR_885932]-
pharmacotherapi[INVESTIGATOR_885933] 
7.1. Treatments Administered 
7.3. Method of Treatment Assignment Removed language, At the time of 
randomization, participants will be 
assigned a randomization number. Numbers should be assigned in 
ascending order and must not be 
omitted or reused. Updated per changes to company procedures 
7.5. Preparation/Handling/Storage/Accountability Corrected storage 
temperature for Hydrogel 
7.7.3. Prohibited Treatments 
During the Study Defined therapi[INVESTIGATOR_014] as non- pharmacotherapi[INVESTIGATOR_885934]-
pharmacotherapi[INVESTIGATOR_885935] 
04DEC2020 Abbreviated CSR 1839-201-021
3

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
9.2.6. Study-Specific 
Definitions for Particular 
Adverse Events Added, If a patient has symptomatic leucocyturia and/or symptomatic 
bacteriuria but does not meet the above criteria for a UTI, 
symptomatic leucocyturia and/or 
symptomatic bacteriuria are recorded individually as adverse 
events and the symptoms (e.g. 
dysuria) are reported separately as well.  Provided additional guidance on how to record events that do not meet the 
protocol-defined adverse 
event of UTI 
04DEC2020 Abbreviated CSR 1839-201-021
4

 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
04DEC2020 Abbreviated CSR 1839-201-021
5

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
Table of Contents 
Title Page .................................................................................................................... .....................[ADDRESS_1239387] of Figures ..................................................................................................................................9  
1. Synopsis ...................................................................................................................... ....10  
2. Schedule of Activities (SoA) ..........................................................................................16  
3. Introduction .................................................................................................................. ...20  
3.1. Study Rationale ............................................................................................................... 20 
3.2. Background .................................................................................................................... .21 
3.2.1.  Overactive Bladder .........................................................................................................21  
3.2.2.  OnabotulinumtoxinA for the Treatment of Overactive Bladder .....................................21  
3.2.3.  Nonclinical Studies .........................................................................................................22  
3.2.4.  Clinical Studies .............................................................................................................. .23 
3.3. Benefit/Risk Assessment ................................................................................................24  
4. Objectives and Endpoints ...............................................................................................25  
Clinical Hypotheses .......................................................................................................................25  
5. Study Design .................................................................................................................. .26 
5.1. Overall Design ................................................................................................................ 26 
5.1.1.  Data Review Committee .................................................................................................27  
5.2. Participant and Study Completion ..................................................................................28  
5.3. End of Study Definition ..................................................................................................28  
5.4. Scientific Rationale for Study Design ............................................................................28  
5.5. Justification for Dose ......................................................................................................29  
6. Study Population .............................................................................................................3 0 
6.1. Inclusion Criteria ............................................................................................................ 30 
6.2. Exclusion Criteria ...........................................................................................................3 2 
6.3. Lifestyle Restrictions ......................................................................................................35  
6.3.1.  Meals and Dietary Restrictions .......................................................................................35  
6.4. Screen Failures ............................................................................................................... .35 
7. Treatments .................................................................................................................... ..36 
7.1. Treatments Administered ................................................................................................36  
7.1.1.  Treatment Regimen and Dosing .....................................................................................37  
7.1.2.  Day of Treatment Criteria ...............................................................................................37  
7.1.3.  Instillation Procedure ......................................................................................................38  
7.1.4.  Study Supplies ................................................................................................................ 39 
7.2. Dose Modification ..........................................................................................................40  
7.3. Method of Treatment Assignment ..................................................................................40  
7.4. Blinding/Masking ...........................................................................................................41  
04DEC2020 Abbreviated CSR 1839-201-021
6

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
7.5. Preparation/Handling/Storage/Accountability ................................................................41  
7.6. Treatment Compliance ....................................................................................................42  
7.7. Concomitant Therapy .....................................................................................................42  
7.7.1.  Prohibited Treatments and Wa shout Before the Study ...................................................42  
7.7.2.  Permitted Treat ments ......................................................................................................42  
7.7.3.  Prohibited Treatments During the Study ........................................................................43  
7.8. Treatment after the End of the Study ..............................................................................43  
8. Discontinuation/Withdrawal Criteria ..............................................................................[ADDRESS_1239388]-void Residual Urine Volume ..................................................................................57  
9.4.5.  Clean Intermittent Catheterization ..................................................................................58  
9.4.6.  Bladder and Kidney Ultrasound......................................................................................60  
9.4.7.  Concomitant Medications and Concurrent Procedures ...................................................60  
9.5. Pharmacokinetics ............................................................................................................60  
9.6. Pharmacodynamics .........................................................................................................60  
9.7. Genetics ..........................................................................................................................60  
9.8. Biomarkers .................................................................................................................... ..60 
04DEC2020 Abbreviated CSR 1839-201-021
7

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
10. Statistical Considerations ................................................................................................61  
10.1.  Sample Size Determination ............................................................................................61  
10.2.  Populations for Analyses ................................................................................................62  
10.3.  Statistical Analyses .........................................................................................................6 2 
10.3.1.  Key Statistical Methodology...........................................................................................62  
10.3.2.  Efficacy Analyses ...........................................................................................................65  
10.3.4.  Safety Analyses ...............................................................................................................67  
10.3.5.  Other Analyses ................................................................................................................ 68 
10.3.6.  Analyses Timepoints and Scope .....................................................................................68  
11. References .................................................................................................................... ...69  
12. Appendices......................................................................................................................72  
12.1.  Appendix 1: Abbreviations and Trademarks ..................................................................72  
04DEC2020 Abbreviated CSR 1839-201-021
8

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
List of Tables 
Table 2-1  Schedule of Activities for Stage 1 of Study 1839-201-021 (All Cohorts) ........[ADDRESS_1239389] of Figures 
Figure 5-1  Schematic of 2-Stage Study Design ..................................................................27  
 
04DEC2020 Abbreviated CSR 1839-201-021
9

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
1. Synopsis 
Protocol Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 
Single-treatment, 2-stage, Dose-finding Study Evaluating the Efficacy and Safety of BOTOXﬁ 
Intravesical Instillation in Participants with Overactive Bladder and Urinary Incontinence 
Protocol Number: 1839-201-021 
Brief Title: BOTOXﬁ Intravesical Instillation in Participants with Overactive Bladder and 
Urinary Incontinence 
Study Rationale: 
For patients with overactive bladder (OAB) a nd urinary incontinence who are inadequately 
managed by [CONTACT_752679][INVESTIGATOR_014], or are not su itable candidates for more invasive therapi[INVESTIGATOR_014], 
there is an unmet medical need for a less in vasive, more convenient OAB treatment option. 
Study 1839-201-021 will investigate the efficacy and safety of BOTOX administered via 
intravesical instillation (BOTOX and Hydrogel [RTGelTM] admixture) which will eliminate the 
need for cystoscopy to administer the treatment,  as well as eliminate th e need for prophylactic 
antibiotic use, and for local anesthesia of the bladder prior to administration. The results of 
Study 1839-201-021 will be used to determine the efficacious and safe dose for future 
investigation in phase 3 clinical trials. 
Objectives and Endpoints: 
Objectives Endpoints 
 To compare the efficacy of a single 
treatment of BOTOX intravesical 
instillation, with possible doses ranging from 100 U up to 500 U, 
with placebo in participants with 
OAB and urinary incontinence   Primary Endpoint: 
 change from baseline at Week 12 (Stage 2) in the average 
number of urinary incontinence epi[INVESTIGATOR_885936]: 
 change from baseline at Week 12 (Stage 2) in the average 
number of micturition epi[INVESTIGATOR_914]  
 change from baseline at Week 12 (Stage 2) in the average 
volume voided per micturition  
 To compare the safety of a single treatment of BOTOX intravesical 
instillation, with possible doses 
ranging from 100 U up to 500 U, with placebo in participants with 
OAB and urinary incontinence   Adverse events, physical examination, vital signs, urine 
dipstick reagent strip test, urinalysis (with urine 
culture/sensitivity, as applicable), hematology and clinical 
chemistry, post-void residual (PVR) urine volume, kidney and bladder ultrasound, urine pregnancy test for women of childbearing potential, concomitant medications, concurrent 
procedures 
04DEC2020 Abbreviated CSR 1839-201-021
10

 
 
Approval Date :  
 20-Dec-2018CONFID
BOTOXﬁ
Purified N
 
Overall 
 Type 
2-stag
4 con
a Up to 4 co
and 500 U
participa n
to procee d
BOTOX 5 0
b Stage 2 wi
results fr o
 
100 U C
DENTIAL 
ﬁ (Botulinum
Neurotoxin 
Study Desi g
of Design: M
ge, dose-find
nsecutive coh
nsecutive coho r
U Cohorts will b e
nts reach Week 6
d with dose esc a
00 U.  
ll begin after co
om the 500 U C o
Cohort 
DRC 
m Toxin Typ
Complex 
gn: 
Multicenter, 
ding study; S
horts and Sta
rts are planned f
e based on inde p
6 in the previou s
alation either to
nfirmation of th
ohort in Stage 1 b
300 U C
pe A)  
randomized
Stage 1 is a p
age 2 is a 5-a
for investigation
pendent Data R e
s cohort. After s a
 BOTOX 400 U f o
e 4 BOTOX dos e
by [CONTACT_16009] 
–
Cohort
DRC 
r
d, double-bli
placebo-cont
arm, placebo
 in Stage 1; the d
eview Committe e
afety review of t
ollowed by [CONTACT_885963] O
es for investigati
4
–
5
DRC 
recommendatProtocol 
ind, placebo -
ntrolled, dose
o-controlled
decision to dos e
e (DRC) review o
the 300 U coho r
OX 500 U or wh e
on in Stage 2 b a
 
400 U Cohort
DRC
 
500 U Cohort
DRC
tion 1839-201-0 2
-controlled, 
e escalation d
d, parallel-gr o
e escalate to 30 0
of unblinded sa f
rt, the DRC will r
ether it is safe t o
ased on unblind e
5
21 Amendm
single-treatm
design with 
oup design.
0 U, possibly 40 0
fety data when a
recommend wh e
o proceed direc t
ed review of saf e
500 U Cohort
DRC
ment 2 
ment, 
3 or 
 
0 U, 
all 
ether 
tly to 
ety 
04DEC2020 Abbreviated CSR 1839-201-021
11

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 Population: Participants with OAB and urgency urinary incontinence w ho have an inadequate 
response to or are intolerant of pharmacologic therapy. (Not e: Pharmacologic therapi[INVESTIGATOR_885937], therapi[INVESTIGATOR_885938].) Protocol-specific 
requirements for inclusion or exclusion of participants are detailed in Sections 6.1 and 6.2 of 
the protocol. 
 Study Treatment Groups:  
Stage 1:  
o 100 U Cohort: 100 U BOTOX intravesical instillation (BOTOX and Hydrogel 
admixture) 
o 300 U Cohort: 300 U BOTOX intravesical instillation (BOTOX and Hydrogel admixture) 
o 400 U Cohort (optional): 400 U BOTOX in travesical instil lation (BOTOX and 
Hydrogel admixture)  
o 500 U Cohort: 500 U BOTOX intravesical instillation (BOTOX and Hydrogel admixture) 
Based on the observed safety data from th e 100 U and 300 U Cohorts, the Data Review 
Committee (DRC) will recommend to proceed  with either BOTOX 400 U followed by 
[CONTACT_310907] 500 U or whether it is safe to dos e escalate directly to BOTOX 500 U.  
Stage 2:  
Four doses of BOTOX will be investigated in  parallel treatment groups as shown below. 
Depending on the outcome of DRC review of safe ty results from the 500 U Cohort in Stage 1, 
BOTOX 500 U may be replaced wi th a BOTOX 200 U treatment group. 
o 100 U BOTOX intravesical instillati on (BOTOX and Hydrogel admixture) 
o 300 U BOTOX intravesical instillati on (BOTOX and Hydrogel admixture)  
o 400 U BOTOX intravesical instillati on (BOTOX and Hydrogel admixture) 
o 500 U BOTOX (option to replace with 200 U)  intravesical ins tillation (BOTOX and 
Hydrogel admixture) 
04DEC2020 Abbreviated CSR 1839-201-021
12

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 Controls:  
Stage 1 and Stage 2: Placebo intravesical  instillation (BOTOX placebo and Hydrogel 
admixture)  
 Dosage/Dose Regimen:  
o For each participant in Stage 1 or Stage 2, a single treatment will be administered on 
Day 1 following fulfillment of the "day of treatment criteria" according to the 
treatment groups outlined above. 
o Study treatment will be administered as a single intravesical instillation through a 
sterile, single-use transurethral catheter us ing aseptic technique as per local site 
practice. A total volume of 60 mL of  study treatment (BOTOX or placebo and 
Hydrogel admixture) will be instilled into the bladder. Subsequen tly, the transurethral 
catheter will be flushed with normal saline at room temperature (~1.5 mL saline for 
females and ~3.0 mL saline for males) to ensure delivery of the small amount of study 
medication remaining in the catheter.   
o After treatment administration, participants  will be instructed to hold the instilled 
study treatment for 60 minutes (or as long as  possible, if less than 60 minutes) and 
remain in the clinic during this time. During the first 30 minutes, participants will be 
kept in a supi[INVESTIGATOR_51115]. The tim e and volume of the participant’s first void 
post-instillation as well as the time to la st visualization of BOTOX (or placebo) and 
Hydrogel admixture in voided urine post-instillation will be recorded. 
 Randomization/Stratification:  
 Participants will be enrolled at clinical study sites into 1 of 2 stages. Initially, 
approximately 50 to 70 participants will enter Stage 1 and be enrolled into one of the dose escalation cohorts (10 participants in  the 100 U Cohort and 20 participants in 
each of the remaining cohorts). Each cohort in Stage 1 will be randomized separately 
and enrollment will be sequential, starting with the 100 U Cohort (BOTOX 100 U or placebo). After review of the safety data from the 500 U Cohort of Stage 1 by [CONTACT_46656], sites will be notified that enrollmen t into Stage 2 may begin. Approximately 
265 participants will be enro lled into Stage 2 and randomized into 1 of 5 parallel 
04DEC2020 Abbreviated CSR 1839-201-021
13

 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
treatment groups, including 4 BOTOX arms and 1 placebo arm. Participants who 
receive study treatment in Stage 1 are not eligible to enroll in Stage 2. 
 At Day 1, participants in both Stage 1 a nd Stage 2 will be randomized centrally to 
receive either a single treatment of BO TOX or matching placebo via intravesical 
instillation. Randomization will be stratified  by [CONTACT_885964][INVESTIGATOR_885939] 2 only.   
 In Stage 1, participants will be randomized  in a 4:1 ratio to receive either BOTOX 
(100 U, 300 U, 400 U [optional], 500 U) or pl acebo. For each cohort in Stage 1, an 
unblinded safety review by [CONTACT_885965] 6. Enrollment into the next cohort at  the higher dose will begin only after the 
DRC has deemed it safe to proceed to the next cohort.   
 In Stage 2, participants will be randomized  in a 1:1:1:1:1 ratio for treatment with 
either BOTOX 100 U, BOTOX 300 U, BOTOX 400 U, BOTOX 500 U (or 200 U), or 
placebo. 
 Confirmation of the BOTOX doses for inve stigation in Stage [ADDRESS_1239390] the BOTOX 500 U treatment 
group with BOTOX 200 U in Stage 2. 
 Visit Schedule:  
04DEC2020 Abbreviated CSR 1839-201-021
14

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
Number of Participants:  
Approximately 70 to 100 participants will be s
creened to randomize ~50 to 70 participants to 
study treatment in Stage 1. Approximately 380 participants will be screened to randomize 
~265 participants to study treatment in Stage 2. 
Number of Sites:  
Stage 1: Approximately 25 sites in the [LOCATION_002]  
Stage 2: Approximately 65 sites in  The [LOCATION_002] and Canada 
Treatment Groups and Study Duration: 
Refer to section on Overall Study Design above for treatment group information. Participation in 
Stage 1 will be a total of 14 weeks (2-week sc reening and 12-week treatment/follow-up period) 
or, if participating in Stage 2, will be a total of 28 weeks (4-week screening and 24-week 
treatment/follow-up period). 
 
04DEC2020 Abbreviated CSR 1839-201-021
15

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
2. Schedule of Activities (SoA) 
04DEC2020 Abbreviated CSR 1839-201-021
16

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
04DEC2020 Abbreviated CSR 1839-201-021
17

 
 
 
 
Approval  Date:  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
04DEC2020 Abbreviated CSR 1839-201-021
18

 
 
 
 
Approval  Date:  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
04DEC2020 Abbreviated CSR 1839-201-021
19

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
3. Introduction 
BOTOXﬁ (Botulinum Toxin Type A) purified neurot oxin complex ([LOCATION_002] adopted name 
[CONTACT_697979]), administered  via intradetrusor injections, is currently approved in more 
than 80 countries worldwide for the treatment of  overactive bladder (OAB) with symptoms of 
urge urinary incontinence, urgency, and frequency,  in adults who have an inadequate response to 
or are intolerant of an anticholinergic medicati on. A new route of administration, intravesical 
instillation, is being developed for the tr eatment of OAB and urinary incontinence.  
3.1. Study Rationale 
Treatment of OAB and urinary incontinence is hi ghly dependent on the needs and capabilities of 
the patient. Treatment frequently begins with ph ysiological interventions such as pelvic muscle 
rehabilitation and fluid and dietary modificat ions. These programs may be combined with 
biofeedback and behavioral therapi[INVESTIGATOR_885940]. When 
physiological and behavioral th erapi[INVESTIGATOR_885941], se cond line pharmacological agents 
may be used to reduce the overac tivity of the detrusor muscle.  
Anticholinergic (antimuscarinic) agents inhibit the binding of acetylcholin e to the cholinergic 
receptors and suppress involuntary detrusor cont ractions, thereby [CONTACT_885966]. Treatment with anticholinergics demonstrat e a profile of good efficacy but with significant 
dose-limiting side effects that often result in poor  patient adherence/discontinuation as evidenced 
by [CONTACT_885967] c use (Chancellor 2016 ). Beta-[ADDRESS_1239391] a profile of minimal/modest efficacy with  cardiovascular side effects and potentially 
significant drug-drug interaction ( Nitti 2013a). After treatment failure with oral or transdermal 
pharmacologic agents for OAB, the only remaini ng options currently available are minimally 
invasive intradetrusor injecti on of BOTOX which has been recommended by [CONTACT_885968] (AUA) and the Eu ropean Association of Urology (EAU) ( Gormley 2015 ; 
Thuroff 2011 ), or other more invasive third line recommended procedures such as implantable 
devices to control incontinence th rough electrical stimulation of the sacral ne rves innervating the 
bladder or surgical bladder augmentation ( Chartier-Kastler 2000; Janknegt 2001 ; Nitti 2013; 
Thiagamoorthy 2016).  
For patients who are inadequately managed by [CONTACT_752679][INVESTIGATOR_014], or are not suitable 
candidates for more invasive therapi[INVESTIGATOR_014], there is an unmet medical need for a less invasive, more 
convenient OAB treatment option.  The BOTOX Instillation program will investigate the delivery 
of BOTOX via intravesical in stillation (BOTOX and Hydrogel1 admixture) in participants with 
                                                 
04DEC2020 Abbreviated CSR 1839-201-021
20

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
OAB. Since BOTOX instillation wi ll be administered via a tran surethral catheter, this new 
delivery option will eliminate the need for cystosc opy to administer the treatment. In addition, it 
will eliminate the need for local anesthesia to the bladder and avoid the use of pretreatment 
antibiotics which are both required for cystosco pic injections of BOTOX in OAB patients. The 
results of Study 1839-201-021 will be used to determine the efficacious and safe dose for future 
investigation in phase 3 clinical trials. 
3.2. Background 
3.2.1. Overactive Bladder 
Overactive bladder (OAB) is a symptom complex th at is characterized by [CONTACT_885969], with or without urgency incontinence, usually with frequency and nocturia (Abrams 2002). In the normal micturition process, inhibitory messages delivered by [CONTACT_885970]. This is accomplished th rough a complex network of innervation between 
the detrusor muscle of the bladder and the micturi tion centers of the brain. When this process is 
disrupted, patients experience urinary urgency and frequency, which is often associated with 
urge incontinence, a combination of symptoms referred to generally as OAB. The condition has 
significant effects on patients social, psychologi cal, and physical well-being, resulting in 
depression, reduced quality of life, and poorer sleep quality ( Stewart 2003 ).  
Epi[INVESTIGATOR_885942] 50 and 
100 million people (Debruyne 2004). In the [LOCATION_002] alone, 16.5% of the population 
(33 million) is estimated to have OAB sympto ms, of which approximately 6.1% experience 
associated urinary incontinence. European stud ies have similarly reported that approximately 
17.0% of the population has sympto ms of OAB with  approximately 6.0% also associated with 
urinary incontinenc e (Milsom 2000 ). OAB increases with age both in men and women 
(Stewart 2003 ). Consequently, it is anticipated that th e condition will become more prevalent as 
the aging population grows larger, thus increa sing the already significant economic burden of 
this disease.  
3.2.2. OnabotulinumtoxinA for the Treatment of Overactive Bladder 
BOTOX intradetrusor injections have been appr oved for neurogenic detrusor overactivity (NDO) 
(BOTOX 200 U) since August 2011 and for OAB (BOTOX 100 U) since January 2013. There are several targets in the bladder that can be inhibited following injection of BOTOX into the 
bladder wall. A direct in hibition of detrusor  contraction through inhibitio n of acetylcholine is a 
clear efferent pathway target ( Coelho 2010 ). In addition to its action on the acetylcholine 
(Ach)-mediated contractions of the detrusor muscle, botulinum toxin serotype A (BoNT/A) may also regulate other vesicle-mediat ed neurotransmitters in both the afferent and efferent pathways 
from the bladder wall, urothelium, or lamina propria ( Apostolidis 2005; Apostolidis 2006; 
Collins 201 3; Fowler 2002; Franks 2000 ; Giannantoni 2006 ; Schulte-Baukloh 2013; Chancellor 
2008). Recent data indicate that BOTOX attenuates the bladder afferent nerves involved in 
04DEC2020 Abbreviated CSR 1839-201-021
21

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
micturition and bladder sensation, suggesting that BOTOX may exert its clinical effects on 
urinary urgency and the other symp toms of OAB syndrome through its marked effect on afferent 
nerves at the level of the urothelium  (Collins 2013).  
3.2.3. Nonclinical Studies 
A series of Good Laboratory Prac tice (GLP) compliant nonclinical  pharmacology and toxicology 
studies with BoNT/A injected into the bladder have been performed. Across all studies BOTOX 
was well tolerated with no evidence of any serious local or systemic effect, no systemic or local 
toxicity, and no significant impact on urodynamics.  
The systemic toxicity of BOTOX and Hydrogel admixture was evaluated in a 1-month, acute 
intravesicular instillation toxi city study  in female rats (20/group) evaluating 
two instillations  of BOTOX a nd Hydrogel admixture at  respective BOTOX dose 
levels of 100, 200, or 400 U/kg at a dose volume of 2 mL/kg. Two additional groups of female 
rats served as control and received either Hydr ogel or saline in the same manner as the treated 
animals. Procedure-related histological findi ngs including inflamma tion and/or urothelial 
hyperplasia in the urinary bladder, ureters, and/ or renal pelvis were observed in all groups 
including the saline control.  There were no adverse findings associ ated with the treatment of the 
BOTOX and Hydrogel admixture up to 400 U/kg (m aximum feasible dose); therefore, the 
established NOEL in the rats was 400 U/kg.  
The local toxicity of BOTOX and Hydrogel admixt ure was also evaluated in a 1-month, acute 
intravesicular instillation t oxicity study  in the standard domestic pig 
(Yorkshire), a model recognized for its similar ity to humans in bladder anatomy and volume, 
with starting weights of around 70 kg. Due to the local nature of the treatment, this allowed for 
instillation of similar drug doses, volume, and con centrations to that planned for humans, and the 
ability to use similar drug produc t instillation pro cesses (ie, techniques an d equipment) to that 
used clinically. In Study , 30 female domes tic Yorkshire pi[INVESTIGATOR_885943] a procedure in 
which a single intravesicular instillation was performed. Nine  animals per group were treated 
with Hydrogel or BOTOX and Hydrogel admixture at a BOTOX dose of 500 U/animal and an 
additional [ADDRESS_1239392] tissues from all groups, in cluding saline control, were consistent with 
spontaneous or incidental backgr ound findings in domestic swine or were attributable to minor 
procedure-associated trauma (hemorrhage in the bladder submucosa), and thus were not 
considered drug-related. 
The BOTOX OAB Instillation Investigators Broc hure provides further detailed information on 
the non-clinical studies. 
04DEC2020 Abbreviated CSR 1839-201-021
22

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
3.2.4. Clinical Studies 
BOTOX Intradetrusor Injection: 
Allergan has completed a clinical development program for intradetrusor injection of BOTOX in 
adult patients with urinary incont inence due to OAB, and it is licensed for use in many countries. 
Where registered, the licensed dose in adults is 100 units (U) BOTOX. A brief summary of 
results is provided below; however, further deta ils can be found in the In vestigators Brochure. 
The dose-finding study (Study 191622-077) evaluated a range of BOTOX doses (50 U, 100 U, 
150 U, 200 U, and 300 U) versus placebo (N = 313) .  The phase 3 program included 2 identical 
pi[INVESTIGATOR_30338] 3 studies in OAB patients who were not adequately managed with anticholinergic 
therapy (Study 191622-095, N = 557 and Study 191622- 520, N = 548). Patients in both studies 
received 100 U BOTOX or placebo administered as intradetrusor injections via cystoscopy. 
Patients could receive an additional treatment of 100 U BOTOX if pre-specified retreatment 
criteria were fulfilled and could enter a l ong-term extension study (Study 191622-096, 3 years 
duration) in which they could receive multiple  treatments of BOTOX (100 U or 150 U BOTOX). 
Both pi[INVESTIGATOR_30338] 3 studies achieved both co -primary efficacy endpoints of significant 
reductions in urinary incontinence at Week 12 and a significantly higher proportion of patients 
reporting their condition as improved or greatly improved on the Treatment Benefit Scale (TBS) 
(Nitti 2013a; Chapple 2013 ). In addition, all secondary endpoints were m et in both pi[INVESTIGATOR_157037], which included OAB symptoms and other HRQL parameters. The duration of effect of BOTOX, based on the first [ADDRESS_1239393] common advers e events remained urological (eg, UTI and 
urinary retention), and the incidence of such a dverse events did not increase with repeated 
BOTOX treatment. 
BOTOX Intravesical Instillation: 
A double-blind, random ized, pi[INVESTIGATOR_885944] ( Krhut 2016 ). A total of  39 females with OAB symptoms were 
randomized for the study into 4 groups, receivin g 50 mL intravesical in stillations  
 
 Key endpoints of the study where the number of urgency grade 3 + 4 
epi[INVESTIGATOR_1841]/72 h, number of leakage epi[INVESTIGATOR_1841]/72 h (both recorded in a 3-day bladder diary), OAB 
04DEC2020 Abbreviated CSR 1839-201-021
23

 
 
A p p r o v a l  D a t e :   
 2 0 - D e c - 2 0 1 8 3 . 3 .  B e n e f i t / R i s k  A s s e s sm e n t  
0 4 D E C 2 0 2 0  A b b r e v i a t e d  C S R  1 8 3 9 - 2 0 1 - 0 2 1 2 4 
 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
4. Objectives and Endpoints 
Objectives Endpoints 
 To compare the efficacy of a single treatment of 
BOTOX intravesical instillation, with possible doses ranging from 100 U to up to 500 U, with 
placebo in participants with OAB an d urinary 
incontinence  Primary Endpoint: 
 change from baseline at Week 12 (Stage 2) in the 
average number of urinar y incontinence epi[INVESTIGATOR_885945]: 
 change from baseline at Week 12 (Stage 2) in the 
average number of micturition epi[INVESTIGATOR_914]  
 change from baseline at Week 12 (Stage 2) in the 
average volume void ed per micturition  
 To compare the safety of a single treatment of 
BOTOX intravesical instillation, with possible 
doses ranging from 100 U to up to 500 U, with placebo in participants with OAB an d urinary 
incontinence   Adverse events (AEs), physical examination, vital 
signs,
 urine dipstick reagent strip test, urinalysis (with 
urine culture/sensitivity, as applicable), hematology and 
clinical chemistry, post-void residual (PVR) urine 
volume, kidney and bladder ultrasound, urine 
pregnancy test for women of childbearing potential, concomitant medications, concurrent procedures 
The efficacy and safety assessm ents are described in Section 9. 
Clinical Hypotheses 
BOTOX intravesical instillation (in one or more of the studied doses) is more effective than 
placebo intravesical instillati on at improving the symptoms of OAB as measured by [CONTACT_885971][INVESTIGATOR_914], and has an acceptable safety profile.
04DEC2020 Abbreviated CSR 1839-201-021
25

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
5. Study Design 
5.1. Overall Design 
This is a multicenter, randomized, double-blind,  placebo-controlled, single-treatment, 2-stage, 
dose-finding study. The total duration of partic ipant participation in Stage 1 is 14 weeks, 
including a 2-week screening and 12-week tr eatment/follow-up period. Total duration of 
participation in Stage 2 is 28 weeks, in cluding a 4-week screening and 24-week 
treatment/follow-up period. 
For Stage 1, BOTOX intravesic al instillation doses (100 U, 300 U, [400 U], 500 U) will be 
investigated in 3 or 4 consecutive cohorts (Figure 5-1 ). Upon completion of the Week [ADDRESS_1239394] 
instillation follow-up timepoint, safety data from each cohort will be reviewed by [CONTACT_885972] (DRC) prior to starting enrollment into the next dose cohort. Based on the observed safety data from the 100 U and 300 U Cohorts, the DRC will recommend to proceed 
with either BOTOX 400 U followed by [CONTACT_310907] 500 U or whether it is safe to dose escalate 
directly to BOTOX 500 U. Each cohort will be randomized in a 4:1 ratio to receive BOTOX or 
placebo. 
Stage 2 will investigate 4 doses of BOTOX ( 100 U, 300 U, 400 U, 500 U [or 200 U]) compared 
to placebo in a 1:1:1:1:1 ratio.  Depending on the outcome of DRC review of safety results from 
the 500 U Cohort in S tage 1, BOTOX 500 U may be replaced with a BOTOX 200 U treatment 
group (Figure 5-1).  
BOTOX or placebo in a Hydrogel ad mixture will be instilled into the bladder as a single 
intravesical instillation through a st erile, single use catheter using aseptic technique per local site 
practice. The total volume to be instilled will be 60 mL. 
The primary efficacy measure will be the number of urinary incontinence epi[INVESTIGATOR_885946] a 3-day participant bladder diary.  Key secondary response measures will be the 
number of micturition epi[INVESTIGATOR_885947] 
a 3-day participant bladder diary. Additiona l measures in Stage 2 will include urodynamic 
parameters
04DEC2020 Abbreviated CSR 1839-201-021
26

 
 
Approval Date :  
 20-Dec-2018CONFID
BOTOXﬁ
Purified N
 
Figure 5- 1
5.1
An indep
Week 6 p
data from
cohort to
100 U C
DENTIAL 
ﬁ (Botulinum
Neurotoxin 
[ADDRESS_1239395]-instillat
m these revie
o the next. In
Cohort 
DRC 
m Toxin Typ
Complex 
Schemati c
ata Review C
C will review
tion follow-u
ews, the DRC
n addition, af
300 U C
pe A)  
c of 2-Sta ge St
Committee
w unblinded
up time poin
C will recom
fter review o
–
Cohort
DRC 
r
tudy Desi gn 
safety data f
nt from each 
mmend to pro
of the safety 
4
–
5
DRC 
recommendatProtocol 
from Stage 1
cohort. Base
oceed with d
data in the 1
 
400 U Cohort
DRC
 
500 U Cohort
DRC
tion 1839-201-0 2
1, upon com
ed on the ob
dose escalati
100 U and 30
5
21 Amendm
mpletion of th
bserved safet
ion from one
00 U Cohort
500 U Cohort
DRC
ment 2 
 
he 
ty 
e 
ts, 
04DEC2020 Abbreviated CSR 1839-201-021
27

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
the DRC will recommend to proceed with dose escalation either to BOTOX [ADDRESS_1239396] the doses of BOTOX 
intravesical instillation for further investigati on during Stage 2 based on unblinded review of the 
safety data from the 500 U Cohort in Stage 1.   
If additional safety data are required by [CONTACT_941] D RC prior to proceeding with dose escalation from 
one cohort (or stage) to the next, additional pa rticipants may be enrolled into a cohort as 
recommended by [CONTACT_16009].   The DRC will remain in place throughout Stage 2 of the study. 
5.2. Participant and Study Completion 
Approximately 70 to 100 participants will be scr eened to randomize ~50 to 70 participants to 
study treatment in Stage 1. Approximately 380 participants will be screened to randomize 
~265 participants to study treatment in Stage 2. 
During Stage 1, participants will be enrolled at ~25 sites in the [LOCATION_002]. During Stage 2, 
participants will be enrolled at ~[ADDRESS_1239397] completed th e study if he/she is a randomized participant who 
was treated, has not been disc ontinued for any reason, attends the scheduled exit visit of the 
respective stage they were enrolled in, a nd is properly discharged from the study. 
5.4. Scientific Rationale for Study Design  
This study is a multicenter, randomized, double- blind, placebo-controlled, single-treatment, 
2-stage, dose-finding study. Stage 1 is a placebo-controlled, dose escalation design with 3 or 4 
consecutive cohorts and Stage 2 is a 5-arm,  placebo-controlled, parallel group design.  
Stage 1 is focused on safety, with a dose-escalat ion design including interim safety assessments 
and DRC reviews between each dose-escalation cohort.  Enrollment into the next cohort at the 
higher dose will begin only after the DRC has deemed  it safe to proceed to the next cohort. The 
2-stage study design allows for an assessment of safety during Stage 1 in a conservative, dose-
escalating manner prior to the in itiation of Stage 2 where the efficacy and safety of BOTOX 
Instillation will be evaluated in a placebo-contro lled, parallel group, 5-arm dose-finding design. 
04DEC2020 Abbreviated CSR 1839-201-021
28

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
Stage 2 is the dose finding portion of the study,  evaluating 4 BOTOX arms and one placebo arm 
(in a 1:1:1:1:1 design). Randomization will be  stratified by [CONTACT_885973][INVESTIGATOR_1841] (≤  9 or > 9 epi[INVESTIGATOR_1841]/day) collected during the screening period and by [CONTACT_885974].   
Both stages of the study will be randomized and double-blind to minimize investigator and 
participant bias, and will provide a placebo compar ator for evaluating the safety and efficacy of 
the various BOTOX instillation doses being studied. In addition, relevant safety parameters 
including adverse events, serious adverse events, physical examinati on, vital signs, urine dipstick 
reagent strip test, urinalysis (with urine cultu re/sensitivity, as applicable), hematology and 
clinical chemistry, post-void residual urine volume, kidney and bladder ultrasound, urine 
pregnancy test for women of childbearing poten tial, concomitant medications and concurrent 
procedures will be closely monitored throughout the study. 
5.5. Justification for Dose 
The approved dose for intradetrusor injection of BOTOX in the treatment of OAB is [ADDRESS_1239398] ug needs to be absorbed through the urothelium 
rather than being directly injected into the bladder muscle. 
The systemic toxicity of BOTOX and Hydrogel admixture was evaluated in a 1-month, 
nonclinical acute intravesicular  instillation toxicity study  in female rats 
evaluating two instillations (3 hours apart) of BOTOX and Hydrogel ad mixture at respective 
BOTOX dose levels of 100, 200, or 400 U/kg,  the NOEL was 400 U/kg (maximum feasible 
dose). The established NOEL in the rats of 400 U/kg provides an approximately 240- and 48-fold 
safety margin to the proposed starting dose of 100 U (1.67 U/kg, based on a 60-kg adult human) 
and maximum dose of 500 U (8.3 U/kg, based on  a 60-kg adult human), respectively, in the 
phase 2 study. The local toxicity of BOTOX a nd Hydrogel admixture was also evaluated in a 
1-month, acute intravesicular instillation toxicity study  in female domestic 
Yorkshire pi[INVESTIGATOR_14107]. A single intravesicular instil lation (volume of ~ 60 mL ) of Hydrogel, BOTOX 
and Hydrogel admixture (at a BOTOX dose of 500 U/animal) or sterile saline, was well tolerated. Microscopic findings in all examined  urinary tract tissues from all groups including 
saline control, were consistent with spontaneous  or incidental background findings in domestic 
swine or were attributable to minor procedure-associated trau ma (hemorrhage in the bladder 
submucosa), and thus were not considered drug-related. 
In the planned phase [ADDRESS_1239399] ogel admixture will be introduced in a single 
cohort of participants at an initial dose of 100 U at a volum e of 60 mL. Following the initial 
cohort, dosing in each subsequent cohort will be ba sed on clinical assessment of the safety data 
from the previous cohort by [CONTACT_73628]. 
04DEC2020 Abbreviated CSR 1839-201-021
29

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
Overall, results from nonclinical studies eval uating intravesical inst illation of BOTOX and 
Hydrogel admixture in female rats and pi[INVESTIGATOR_885948]-established nonclinical safety 
data and clinical safety profile of BOTOX injection (including cumulative intramuscular 
injections across indications of up to 500 U as well as previous OAB and NDO development 
programs with intradetrusor injections up to 300 U), support the initiation of the phase [ADDRESS_1239400] an 
inadequate response to or are intolerant of  pharmacologic therapy.  
 
6.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
1. Age 
1.[ADDRESS_1239401] be 18 to 75 years old at the ti me of signing the informed consent.  
2. Type of Participant and Disease Characteristics 
2.01 Has symptoms of OAB (frequency and urgenc y) with urgency urinary incontinence 
for a period of at least 6 months immediately prior to  screening, determined by 
[CONTACT_885975]. 
04DEC2020 Abbreviated CSR 1839-201-021
30

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
2.04 Has not been adequately managed with ≥ 1 pharmacologic therapi[INVESTIGATOR_885949] (ie, anticholinergics or beta-3 agonists), in the opi[INVESTIGATOR_1070]. 
4. Sex 
4.[ADDRESS_1239402] result (f or women of childbearing potential).  
6. Informed Consent 
6.[ADDRESS_1239403] icable (eg, Written Authorization for Use 
and Release of Health and Research Study Information (US sites) and written Data 
Protection consent (EU sites).  
04DEC2020 Abbreviated CSR 1839-201-021
31

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
6.2. Exclusion Criteria 
Participants are excluded from the study if  any of the following criteria apply: 
1. Medical Conditions 
1.01 Has symptoms of OAB due to any known neur ological condition (eg, spi[INVESTIGATOR_1828], 
multiple sclerosis, cerebrovascular accident, Alzheimers disease, Parkinsons disease, 
etc).  
1.02 Has a predominance of stress incontinence in the opi[INVESTIGATOR_871], as 
determined by [CONTACT_522771]  
1.03 Has history or evidence of any pelvic or ur ological abnormalities
04DEC2020 Abbreviated CSR 1839-201-021
32

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
04DEC2020 Abbreviated CSR 1839-201-021
33

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
2.03 Has had previous or current botulinum toxin therapy of any serotype for any urological 
condition. 
04DEC2020 Abbreviated CSR 1839-201-021
34

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
6.3. Lifestyle Restrictions 
6.3.1. Meals and Dietary Restrictions 
There are no  specific requirements regarding di et.  
 
 
  
6.4. Screen Failures 
Screen failures are defined as participants who c onsent to participate in the clinical study but are 
not subsequently randomized to treatment . A minimal set of screen failure information is 
required to ensure transparent re porting of screen failure particip ants to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publis hing requirements and to respond to queries 
from regulatory authorities. Minimal informati on includes demography, screen failure details, 
eligibility criteria, and any serious adverse event (SAE). 
04DEC2020 Abbreviated CSR 1839-201-021
35

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
7. Treatments 
Study treatment is defined as any investigationa l treatment(s), marketed product(s), placebo, or 
medical device(s) intended to be administer ed to a study participant according to the study 
protocol. 
7.1. Treatments Administered 
Study 
Treatment 
Name  [CONTACT_885989] X Placebo and Hydrogel Admixture  
Dosage 
Formulation  BOTOX  
 Clostridium 
botulinum toxin Type A in a sterile vacuum-
dried form to be reconstituted with 0.9% 
sterile saline (without preservative)   
Hydrogel (RTGel
TM)  
Each vial of Hydrogel 
contains 
 
  
 
BOTO
X and Hydrogel Admixtureb: 
Reconstituted BOTOX to be administered 
with Hydrogel for intravesical instillation BOTOX Placebo : 
each vial contains 0.9 mg  of sodium chloride 
in a sterile, vacuum-dried form to be reconstituted with 0.9% sterile saline 
(without preservative)  
 
Hydrogel (RTGel
TM)  
: Each vial of Hydrogel 
contains 
 
   
 BOTOX Placebo 
and Hydrogel Admixtureb: 
Reconstituted BOTOX Placebo to be 
administered with Hydr ogel for intravesical 
instillation 
Route of Administration   Intravesical instillation Intravesical instillation 
Dosing Instructions  Single treatment (60 mL volume) administered by [CONTACT_885976] a transurethral catheter. Single treatment (60 mL volume) administered by [CONTACT_885976] a transurethral catheter 
Packaging and Labeling BOTOX will be provided in vials in identical packaging and labeling to placebo. 
 
 
  BOTOX Placebo will be pr ovided in vials in 
identical packaging and labeling to BOTOX. 
 
 
Manufacturer BOTOX: Allergan Inc. Hydrogel (RTGel
TM):  BOTOX Placebo: Allergan Inc. Hydrogel (RTGel
TM):  
04DEC2020 Abbreviated CSR 1839-201-021
36

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
7.1.1. Treatment Regimen and Dosing 
All eligible participants enro lled into the study will receive a single double-blind treatment of 
either BOTOX or placebo for Stage 1 or Stage 2 as follows: 
Stage 1 
 100 U Cohort: 100 U BOTOX intravesical instillation (BOTOX and Hydrogel admixture) 
(n = 8) or placebo (n = 2) 
 300 U Cohort: 300 U BOTOX intravesical instillation (BOTOX and Hydrogel admixture) (n = 16) or placebo (n = 4) 
 400 U Cohort (optional): 400 U BOTOX intrav esical instillation (BOTOX and Hydrogel 
admixture) (n = 16) or placebo (n = 4) 
 500 U Cohort: 500 U BOTOX intravesical instillation (BOTOX and Hydrogel admixture) (n = 16) or placebo (n = 4) 
Based on the observed safety data from the 100 U and 300 U Cohorts, the DRC will recommend to proceed with either BOTOX 400 U followed by [CONTACT_310907] 500 U or whether it is safe to dose 
escalate directly to BOTOX 500 U.  
Stage 2 
 100 U BOTOX intravesical instillation (BOT OX and Hydrogel admixture) (n = 53) 
 300 U BOTOX intravesical instillation (BOT OX and Hydrogel admixture) (n = 53) 
 400 U BOTOX intravesical instillation (BOT OX and Hydrogel admixture) (n = 53) 
 500 U (option to replace with 200 U) BOTO X intravesical instillation (BOTOX and 
Hydrogel admixture) (n = 53) 
 BOTOX Placebo intravesical instillation (Pla cebo and Hydrogel admixture) (n = 53)  
The four BOTOX doses for investigation in Stag e [ADDRESS_1239404] be fulfilled prior to administration of study 
treatment at randomization/Day 1: 
 Central laboratory urine analysis results for possible UTI have been reviewed 
04DEC2020 Abbreviated CSR 1839-201-021
37

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 Negative urine dipstick reagent strip test (for nitrates and leukocyte esterase) performed at 
the study site 
 Participant is asymptomatic for a UTI, in the opi[INVESTIGATOR_871] 
 Negative urine pregnancy test for women of childbearing potential 
 Investigator continues to deem that no c ondition or situation exists which, in the 
investigators opi[INVESTIGATOR_1649], puts the participant at significant risk from receiving an intravesical 
instillation of BOTOX 
7.1.3. Instillation Procedure 
Treatment administration must be performed by [CONTACT_093], subinvestigator(s) or study site 
personnel qualified to place a transurethral catheter. 
In order to provide guidance to  qualified site personnel who have  been delegated the role of 
study treatment administrator, the in vestigator is expected to perf orm or be present for at least 
the first instillation procedure performed at the site. 
04DEC2020 Abbreviated CSR 1839-201-021
38

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
04DEC2020 Abbreviated CSR 1839-201-021
39

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
7.2. Dose Modification 
Not applicable. 
7.3. Method of Treatment Assignment 
Prior to initiation of study treatment, each pa rticipant who provides informed consent will be 
assigned a participant number that  will serve as the pa rticipant identification number on all study 
documents. 
For Stage 1, participants will be randomized  centrally on randomization/Day 1 using an 
automated randomization system to 1 of 2 treatment  groups within each c ohort in a 4:1 ratio to 
receive BOTOX and Hydrogel admixture or placebo and Hydrogel admixture.  For Stage 2, participants will be randomized and stratified centrally on randomization/Day 1 by 
[CONTACT_885977][INVESTIGATOR_1841] ( ≤ 9 or > 9 epi[INVESTIGATOR_1841]/day) and sex collected 
during the screening period. Each participant within a stratification group will be randomized 
using an automated randomization system to 1 of 5 treatment arms (BOTOX 100 U and 
Hydrogel admixture, BOTOX 300 U and Hydroge l admixture, BOTOX 400 U and Hydrogel 
admixture, BOTOX 500 U [or BOTOX 200 U] a nd Hydrogel admixture, placebo and Hydrogel 
admixture) in a ratio of 1:1:1:1:1. 
04DEC2020 Abbreviated CSR 1839-201-021
40

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
7.4. Blinding/Masking 
All investigational study treatments (BOTOX a nd placebo) will have identical packaging and 
labeling to maintain masking of the study. Study tr eatments will be identifi ed as investigational 
compounds.  
The Hydrogel will not be masked and will be provided to sites in an open-label fashion. 
Hydrogel for intravesical instillation with BO TOX/BOTOX Placebo will be  identified as an 
investigational compound.  
When necessary for the safety and proper treatmen t of the patient, the investigator can unmask 
the participants treatment assignment to determine which treatment has been assigned and 
institute appropriate follow-up care.  When po ssible, the sponsor (All ergan Medical Safety 
Physician) should be notified pr ior to unmasking study medication.  The investigator should 
inform the sponsor (Allergan Medical Safety Physician) of the unmasking if there is no 
notification prior to the unmasking. 
7.5. Preparation/Handling/Storage/Accountability 
Detailed reconstitution instruc tions will be included in the Study Pharmacy Manual.  
The study medication must be stored in a secure  area and administered only to participants 
entered into the clinical study, at no cost to the participant, in accordance with the conditions 
specified in this protocol. Only  authorized site staff may suppl y or administer study treatment. 
04DEC2020 Abbreviated CSR 1839-201-021
41

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
All clinical study medications/treatments and/or supp lies will be returned to Allergan or Allergan 
designee for destruction or destroyed at the site as specified in writing by [CONTACT_78562]. 
7.6. Treatment Compliance 
Study treatment will be administered by [CONTACT_885978] 
a transurethral catheter. 
7.7. Concomitant Therapy 
The use of any concomitant medication, prescripti on or over-the-counter, is to be recorded on the 
participants electronic case report form (e CRF) at each visit along with the reason the 
medication is taken. 
7.7.1. Prohibited Treatments and Washout Before the Study 
Prohibited medication washout of pharmacologic th erapy to treat symptoms of OAB, including 
nocturia, must be complete prior to the first screening procedure.  
 
7.7.2. Permitted Treatments 
Any medication or vaccine (including over-the-c ounter or prescription medicines, vitamins, 
and/or herbal supplements) that th e participant is receiving at the time of enrollment or receives 
during the study must be  recorded along with: 
 Indication 
 Dates of administration incl uding start and end dates 
 Dosage information including dose and frequency 
Therapy considered necessary for the participant s welfare may be given at the discretion of the 
investigator. If the permissibility of a specific me dication/treatment is in question, please contact 
[CONTACT_456]. 
The sponsor or designee should be contact[CONTACT_397038] e any questions regarding concomitant or 
prior therapy. Caution is advised if the participant requires treat ment with aminoglycoside antibiotics or curare-
like agents during the course of the study. This is due to the potentia l interaction of these 
04DEC2020 Abbreviated CSR 1839-201-021
42

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
treatments with BOTOX, which may affect the ne uromuscular junction and may therefore result 
in an unpredictable effect on muscle weakness. 
7.7.3. Prohibited Treatments During the Study 
The decision to administer a prohibited medicati on/treatment is done with the safety of the study 
participant as the primary consid eration. When possible, Allergan  should be notified before the 
prohibited medication/treat ment is administered. 
Prior botulinum toxin treatment of any serotype  for any urological condition is prohibited. 
7.8. Treatment after the End of the Study  
Not applicable. 
04DEC2020 Abbreviated CSR 1839-201-021
43

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
8. Discontinuation/Withdrawal Criteria  
Participants may voluntarily withdr aw from the study at any time. 
Notification of early participant discon tinuation from the study and the reason for 
discontinuation will be made to the sponsor and will be clearly documented on the appropriate 
eCRF. If a participant ex its the study prior to study completion, all exit visit assessments should 
be performed at the time of exit. 
8.1. Discontinuation of Study Treatment  
See the schedule of activities for data to be coll ected at the time of treatment discontinuation and 
follow-up and for any further evaluati ons that need to be completed. 
Reasons for discontinuation from the study tr eatment and/or the study may include the 
following: 
 Adverse event 
 Completed 
 Death 
 Failure to meet randomization criteria  
 Lack of efficacy 
 Lost to follow-up 
 Other 
 Pregnancy 
 Protocol deviation 
 Site terminated by [CONTACT_3211] 
 Study terminated by [CONTACT_3211] 
 Technical problems 
 Withdrawal by [CONTACT_3445] 
04DEC2020 Abbreviated CSR 1839-201-021
44

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
These terms are defined in Appendix 5. 
8.2. Withdrawal from the Study 
 A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, 
or administrative reasons. 
 Participants must be discontinued from the st udy and/or receive no furt her study treatment, if 
any of the following criteria are met: 
o Participant develops (or has an exacerba tion of) any medical condition or adverse 
event that, in the opi[INVESTIGATOR_871], would put the participant at an 
unacceptable medical risk or compromises the participants ability to participate in 
the study 
o Participant become s pregnant (see Section 9.2.5) 
o Participant is diagnosed with new or recurrent malignancy, except basal cell 
carcinoma 
o Participant is unwilling or unable to con tinue to comply with study procedures 
 If the participant withdraws consent for disclo sure of future information, the sponsor may 
retain and continue to use a ny data collected before such  a withdrawal of consent. 
 If a participant withdraws from the study, he /she may request destruction of any samples 
taken and not tested, and the investigator must  document this in the site study records. 
 Participants should be followed for at least [ADDRESS_1239405] study treatmen t. All participants 
who prematurely discontinue from the study, unless the cause is screen failure, should be 
seen for a final assessment at early termination. A final assessment will be defined as completion of the evaluations scheduled for th e final visit at Week 12/Exit for Stage 1 or 
Week 24/Exit for Stage 2. 
 The investigator and Allergan also have the ri ght to withdraw a partic ipant from the study at 
any time for any reason. 
 Where possible, the decision to  withdraw a participant from  study treatment or the study 
should be discussed with Allergan. 
04DEC2020 Abbreviated CSR 1839-201-021
45

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
8.3. Lost to Follow Up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  
9. Study Assessments and Procedures 
 Study procedures and their timing are summari zed in the schedule of  activities (Section 2 ).  
 Protocol waivers or exem ptions are not allowed. 
 Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to dete rmine if the participant should  continue or discontinue study 
treatment. 
 Adherence to the study design requirements, in cluding those specified in the schedule of 
activities, is essential an d required for study conduct. 
 All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened a nd to confirm eligibility or record reasons for 
screening failure, as applicable.  
 Screening procedures can commence once the informed consent and data 
authorization/protection form have been obtai ned. Screening will be considered to have 
started at the time of the first screening activ ity or procedure, and completed when all the 
required inclusion/exclusion criteria have been met and the patient is randomized at Day 1. 
04DEC2020 Abbreviated CSR 1839-201-021
46

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
Screening procedures should be completed as soon as possible, with a maximum of -14 day 
window from randomization/Day 1 for Stag e 1 and maximum of -28 day window from 
randomization/Day [ADDRESS_1239406] result and needs to be 
treated for a UTI, the screening period can be extended by [CONTACT_8622] 14 days. Screening 
procedures may be repeated during this time, as deemed clinically necessary, at the discretion 
of the investigator (eg, repeat the 3-day bl adder diary if patient had a symptomatic UTI 
during initial diary collection). 
 Evaluations should be performed by [CONTACT_742637].   
9.1. Efficacy Assessments 
Only Stage 2 is powered for an inferential efficacy analysis. 
9.1.1. Primary Efficacy Measure 
Number of epi[INVESTIGATOR_885950], as recorded in the participant bladder diary 
over 3 consecutive days during the week prior to  each study visit. The primary timepoint is at 
Week 12. 
9.1.2. Secondary Efficacy Measures 
 Number of epi[INVESTIGATOR_885951] r day (both by [CONTACT_885979], if required) as recorded in the participant bladder diary over 3 consecutive 
days during the week prior to each study visit. 
 Volume voided per micturition as recorded over one 24-hour period dur ing the 3-day bladder 
diary (divided by [CONTACT_885980] 24-hour period). 
04DEC2020 Abbreviated CSR 1839-201-021
47

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
04DEC2020 Abbreviated CSR 1839-201-021
48

 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
 
04DEC2020 Abbreviated CSR 1839-201-021
49

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
04DEC2020 Abbreviated CSR 1839-201-021
50

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
9.2. Adverse Events 
The definitions of an AE or SAE can be found in Appendix 3. 
AEs will be reported by [CONTACT_2299].  
The investigator and any design ees are responsible for detecti ng, documenting, and recording 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study treatment or study procedur es, or that caused the 
participant to discontinue the study  (see Section 8).  
9.2.1. Time Period and Frequency for Co llecting AE and SAE Information  
All SAEs from the signing of the ICF until [ADDRESS_1239407] follow-up visit will be collected 
at the timepoints specified in the schedule of activities (Section 2), and as observed or reported 
spontaneously by [CONTACT_19288]. 
All AEs from the signing of the ICF until the last follow-up visit will b e collected at the 
timepoints specified in the sc hedule of activities (Section 2), and as observed or reported 
spontaneously by [CONTACT_19288]. Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on th e AE section of the eCRF. 
All SAEs will be record ed and reported to the sp onsor or designee within 24 hours, as indicated 
in Appendix 3 . The investigator will subm it any update d SAE data to the sponsor within 
24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE information in former study 
participants. However, if the investigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and he/she considers the event to be reasonably 
related to the study treatment or study participation, the investig ator must promptly notify the 
sponsor. 
The method of recording, evaluating, and a ssessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3. 
9.2.2. Method of Detecting AEs and SAEs 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of  the participant is the preferred method to inquire about 
AE occurrences.  
04DEC2020 Abbreviated CSR 1839-201-021
51

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
9.2.3. Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All AEs/SAEs  will be followed until reso lution, stabilization, until 
the event is otherwise explained, or the particip ant is lost to follow-up (as defi ned in Section 8.3).  
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_325740]/or causa lity of the AE or SAE as fully as possible. This may include 
additional laboratory tests or inve stigations, histopathological exam inations, or consultation with 
other health care professionals. 
New or updated information will be record ed in the originally completed eCRF. 
The investigator will submit any updated SAE data to the sponsor within 24 hours of receipt of 
the information. 
9.2.4. Regulatory Reporting Requirements for SAEs 
 Prompt notification by [CONTACT_325741] a 
study treatment under clinical investigation are met.  
 The sponsor has a legal responsibility to notify both the local regulato ry authority and other 
regulatory agencies about the safety of a st udy treatment under clinical  investigation. The 
sponsor will comply with country-specific re gulatory requirements relating to safety 
reporting to the regulatory authority, institut ional review boards (IRBs)/independent ethics 
committees (IECs), and investigators.  
 Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) according to local regu latory requirements and sponsor policy and 
forwarded to investigators as necessary. 
 An investigator who receives an  investigator safety report de scribing a SAE or other specific 
safety information (eg, summary or listing of SAEs) from the sponsor will review and then 
file it and will notify the IRB/IEC, if appropriate acco rding to local requirements. 
9.2.5. Pregnancy 
Urine pregnancy testing will be conducted for women of childbearing potential at screening, Day 1 (prior to treatment), and at  each follow-up clinic visit. See Appendix 4 f or detailed 
information on definition of women of childbearing potential, use of contraceptives and pregnancy.   
04DEC2020 Abbreviated CSR 1839-201-021
52

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
If a female becomes pregnant during the study, th e investigator should inform the sponsor within 
[ADDRESS_1239408] udy after appropriate safety follow-up.   
Details of all pregnancies in female participan ts will be collected after the start of study 
treatment. The investigator will (1) notify the participants physician that the participant was being treated with the investigational drug, and (2) follow the progress of the pregnancy. The 
investigator must document the outco me of the pregnancy and provide a copy of the 
documentation to Allergan. Please see Appendix 4 for further inform ation on collection of 
pregnancy information 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs. 
9.2.6. Study-Specific Definitions for Particular Adverse Events  
Definition of Adverse Event of Urinary Retention 
An adverse event of urinary retention should only be  recorded when a participant has an elevated 
PVR that requires intervention with CI C according to the following criteria: 
 Participant has a PVR of ≥ 350 mL (regardless of symptoms), OR 
 Participant has a PVR ≥ 200 mL and < 350 mL and the pa rticipant reports associated 
symptoms ie, voiding difficulties, sensation of bladder fullness that in the investigators 
opi[INVESTIGATOR_165527]. 
Definition of Adverse Event of Residual Urine Volume 
An adverse event of residual urine volume should be recorded if, in the investigators opi[INVESTIGATOR_1649], 
the raised PVR is clinically significant but does not fulfill the above definition for urinary 
retention. 
The investigator should use th e information from the regular assessment of PVR urine volume 
and the need to catheterize for elevated PVR to  assess the stop date of the adverse events. 
Definition of Adverse Event of Urinary Tract Infection 
An adverse event of UTI will be recorded if  all of the following criteria are fulfilled: 
 Participant has symptoms of a UTI (eg, pa inful urination, fever, hematuria, etc) 
 A positive urine culture result with a bacteriuria count of > 105 CFU/mL 
 Leukocyturia of > 5/hpf. 
04DEC2020 Abbreviated CSR 1839-201-021
53

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
If a patient has symptomatic leucocyturia and/or  symptomatic bacteriuria but does not meet the 
above criteria for a UTI, symptomatic leucocyt uria and/or symptoma tic bacteriuria are 
recorded individually as adverse events and the symptoms (e.g. dysuria) are reported separately 
as well. 
If a participant reports a UTI to  the investigator which was ev aluated by a physician not at the 
investigative site (eg, primary care physician or emergency room), then all reasonable attempts 
will be made to obtain the confirmatory urine analysis and culture/sensitivity results. If a participant is asymptomatic, but has:   
 a clinically significant bacteriuria (with or withou t leucocyturia), this should be reported as 
asymptomatic bacteriuria. 
 a clinically significant leucocyturia, (with or without bacteriuria), this should be reported as 
leucocyturia 
9.3. Treatment of Overdose 
The LD 50 for BOTOX in humans is estimated from primate studies to be approximately 3000 U. 
This makes accidental in jection of a lethal dose  highly unlik ely, but significant AEs may still 
occur at doses below the LD 50 (Herrero 1967 ; Scott 1989). Excessive doses m ay produce local, 
or distant, generalized, and profound neuromuscular paralysis. Should accident al injection or oral 
ingestion occur or overdose be su spected, the patient should be  medically monitored for up to 
several weeks for progressive signs or symptoms of systemic muscular weakness that could be 
local or distant from the site of injection,  which may include ptosis, diplopia, dysphagia, 
dysarthria, generalized weakness, or respi[INVESTIGATOR_182569]. Please refer to the BOTOX (OAB 
Instillation) Investigators Broc hure (General Section; Section 6. 5 Overdose) for further details. 
In the event of an overdose,  the investigator should: 
1. Contact [CONTACT_10990]. 
2. Closely monitor the participant for AE s/SAEs and laboratory abnormalities. 
3. Document the quantity of the excess dose, as we ll as other details that led to overdose, in 
the eCRF.  
9.4. Safety Assessments 
Planned timepoints for all safety assessm ents are provided in the schedule of activities 
(Section 2). 
04DEC2020 Abbreviated CSR 1839-201-021
54

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
9.4.1. Physical Examinations 
The physician or appropriately qualified designe e will perform a complete physical examination 
and examine the participant for any physical abnormalities of the following body systems: head, 
ears, eyes, nose, and throat (HEENT), neck, heart/cardiovascular, pulmonary, abdomen, 
musculoskeletal, skin, and genitourinary (full pelvic and rectal examination for females and rectal exam ination for males). Physical exam ination will be performed at the appropriate 
scheduled visits ( Table 2-1 and Table 2-2). 
9.4.2. Vital Signs 
Vital signs will be measured as outlined below: 
 pulse rate (beats per minute) : participants should be resting in a seated position 
 blood pressure (mm Hg): participan ts should be resting in a seated position. Systolic/diastolic 
blood pressure is then measur ed with a sphygmomanometer 
 temperature (
oF or oC): participants should be seat ed and the body temperature taken 
according to local site practice 
 body weight (screening and exit visits) and heig ht (Screening visit only) will be measured 
according to local site practice 
Please see the schedul e of study visits ( Table 2-1 and Table 2-2) for the visits at which vital signs 
should be assessed. 
9.4.3. Clinical Safety Laboratory Assessments 
All clinical laboratory samples will be analyzed  
 
 
Analytes will be tested as specified below: 
Hematology: red blood cells (RBC); white blood cells (WBC); WBC differential (% and 
absolute): neutrophils, lymphocytes, monocytes, eosinophils, basophils, hematocrit, hemoglobin, 
platelets Blood Chemistry: albumin, alkaline phosphatase , alanine aminotransferase (ALT [SGPT]), 
aspartate aminotransferase (AST [SGOT]), total and direct bilir ubin, blood urea nitrogen (BUN), 
calcium, chloride, creatinine, gamma glutamyltr ansferase (GGT), globulin, nonfasting glucose, 
potassium, total protein, and sodium 
04DEC2020 Abbreviated CSR 1839-201-021
55

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
Urinalysis and Urine Culture and Sensitivity: Urin alysis will be performed at all clinic study 
visits as applicable; a urine culture and sensitivity test will also be performed as determined by 
[CONTACT_885981] a UTI (positive leukocyte 
esterase, nitrites, blood and/or microscopic sedime nts such as WBCs, RBCs , and/or bacteria).  
Urine analytes to be te sted are listed below: 
o Urinalysis: color, appearance,  specific gravity, pH, protein, glucose, ketones, occult 
blood, leukocyte esterase, nitrite, bilir ubin, urobilinogen, crystals; microscopic 
examination if positive for protein, leukocyte, occult blood, nitrite, or crystals 
o Urine Culture and Sensitivity: culture, quantitation, isolation, identification, and 
susceptibility 
Urine Dipstick Reagent Test (Urine Dipstick) Tes t: The urine dipstick is used to identify a 
potential UTI and to provide immediate information to the investigator.  If positive for nitrites and/or leukocyte esterase, indica ting a possible infecti on, the participant should be treated with 
antibiotics per the clinical judgmen t of the investigator and in acco rdance with local site practice. 
Urine analysis, urine culture and sensitivity test ing (performed from a sample collected on the 
same day as the dipstick) will be used to confirm the presence or absence of a UTI. If UTI is present, sensitivity testing will provide additiona l information to the investigator regarding 
pathogen susceptibility to the antibiotic select ed for treatment based on the positive dipstick.  
 Screening urine dipstick reagent strip test re sults: If positive, the screening period can be 
extended by [CONTACT_8622] 14 days (ie, a total maximum of 28 days for Stage 1 and 42 days for Stage 
2) to accommodate the additional time required for antibiotic treatment. Some of the 
screening procedures may be repeated, as deem ed clinically necessary , at the discretion of 
the investigator (eg, repeat th e screening bladder di ary if participant had a symptomatic UTI 
during initial diary collection). 
 Randomization/Day [ADDRESS_1239409] results: Participants with a dipstick 
positive for nitrites and/or leukocyte esterase at randomization/Day 1 do not meet day of 
treatment criteria and therefore must not receive study treat ment. The participant should be 
treated with antibiotics per th e clinical judgment of the inve stigator and in accordance with 
local site practice and may return for a resche duled randomization/Day 1 visit (within a total 
maximum of 28 days of starting screening pro cedures for Stage 1 and a total maximum of 42 
days of starting screening procedures for Stage 2). If the dipstick obtain ed at the rescheduled 
randomization/Day 1 visit is negative for nitr ites and leukocyte estera se and all day of 
treatment criteria are fulfilled, the participant can be treated.  
Urine cytology: Urine cytology is performed at the screening vis it only. Abnormal urine 
cytology suspi[INVESTIGATOR_271] a urothelial malignancy should be investigated by [CONTACT_165566], and only if such  malignancy is ruled out should the participant be 
enrolled. Results of the investigation will be recorded in the source documents.  
04DEC2020 Abbreviated CSR 1839-201-021
56

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
Prostate-specific Antigen (PSA): PSA levels will be measured at screening in male participants. 
Urine Pregnancy Test: Urine pregnancy testing will be conducted for women of childbearing 
potential. 
9.4.4. Post-void Residual Urine Volume 
PVR urine volume is assessed by [CONTACT_885982] r scan after the participant has performed a 
voluntary void. If a participant is required to  begin use of CIC post treatment, the PVR urine 
volume will be measured after the participant has attempted to void voluntarily and prior to a 
catheterization. If a participant is not able to s pontaneously void despi[INVESTIGATOR_885952], then this will be 
recorded on the CRF and the PVR will not be measured. 
After randomization, should a PVR urine volume indicate a clinically mean ingful elevation, the 
participant should be asked to void once again (a llowing the participant sufficient time to void). 
The PVR urine volume will then be re-assessed. For participants who have a PVR urine volume 
measurement repeated, only the repeat value sh ould be recorded in the eCRF. Guidance on how 
to manage an elevated PVR, observed at any rout ine study visit or addition al follow-up visit is 
provided. In summary, posttreatment PVR urine volume is divided into 3 categories:  i) < 200 mL 
ii) between ≥ 200 mL and < 350 mL 
iii) ≥ 350 mL  
Protocol required action depends  on the PVR category as does the need for further visits to 
evaluate the participant. The need for CIC is  also dependent on the PVR as well as the 
participant symptoms. This guidance is to ensure  participants are appropriately followed up and 
CIC is only initiated when required (while also ensuring any unnecessary in tervention is limited). 
Further details are given below. This guidance does not preclude further actions if the investigator deems it necessary. 
i) PVR < 200 mL 
No protocol required action needs to be taken. Participant continues to be followed as per the 
schedule of visits and procedures. 
ii) PVR ≥ 200 mL and < 350 mL 
If a PVR of ≥ 200 mL but < 350 mL is identified at any posttreatment visit, the investigator will 
assess the participant for any s pontaneously reported associated symptoms (such as voiding 
difficulties or sensation of bladder fullness), wi th the resulting action to be as follows:  
04DEC2020 Abbreviated CSR 1839-201-021
57

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
a) If a participant reports asso ciated symptoms that in the opi [INVESTIGATOR_885953], then CIC should be mana ged as detailed in th e CIC section (Section 9.4.5). 
b) If a participant does not report any symptoms or if they report associated symptoms that, in 
the opi[INVESTIGATOR_871], do not requ ire CIC then the following will occur: 
 The participant will be seen for an additional follow-up visit 1 week later, at which time the 
PVR and any associated symptoms will be rea ssessed and central laboratory urine analysis 
and culture/sensitivity will be perfor med. At this reassessment visit: 
o if the PVR is increasing and is associated with symptoms, that in the investigators 
opi[INVESTIGATOR_165527], then CIC should be initiated and managed as detailed below in 
the CIC section 
o if the PVR is ≥  350 mL then CIC should be initiated and managed as detailed below 
in the CIC section 
o if the PVR is increasing but is not associat ed with symptoms or is associated with 
symptoms that in the opi[INVESTIGATOR_2511] i nvestigator do not require CIC, then the 
participant will be seen 1 week later to determine if CIC has become warranted and should be initiated based on PVR and/or any associated symptoms. At this additional 
reassessment visit: 
 a central laboratory urine analysis an d culture/sensitivity will be collected 
 if in the investigators judgment CIC should be initiated, then CIC should be 
managed as detailed below in the CIC section 
 if CIC is not initiated and PVR continues to increase, the investigator will determine whether additional follow-up visits should occur 
o If the PVR is decreasing or is unchanged then the participant will continue per the 
protocol schedule of visits and procedures. 
iii) PVR ≥ 350 mL 
If a PVR of ≥ 350 mL is identified at any posttreatment  visit (regardless of symptoms) then CIC 
will be initiated as detailed in the CIC section. 
9.4.5. Clean Intermittent Catheterization 
The following guidance should be used for the initia tion of CIC in this study. Sterile, single use 
intermittent catheters should be used. Indwelling catheters should not be used in this study.   
04DEC2020 Abbreviated CSR 1839-201-021
58

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
Initiation of Clean Intermittent Catheterization 
As described above in the PVR section, CIC shoul d be initiated per protocol when one of the 
following criteria is fulfilled: 
 PVR is ≥ [ADDRESS_1239410] less of whether the participant reports 
associated symptoms 
 PVR is ≥ 200 mL and < 350 mL and the participant spontaneously reports associated 
symptoms (ie, voiding difficulties, sensation of bladder fullness) that in the opi[INVESTIGATOR_165525]. 
The following will occur when initiating CIC (for elevated PVR as described above): 
1. CIC is implemented and the participant should be instructed to perf orm CIC using sterile, 
single-use catheters (which will be provided to the participant) 
2. An adverse event of urinary retention is recorded 
3. Central laboratory urine analysis and cultu re/sensitivity are performed as per routine 
requirements at each study visit 
4. The participant will be seen for a follow-up vi sit 1 week later where the PVR, associated 
symptoms, central laboratory urine analysis a nd culture/sensitivity will be reassessed. The 
investigator will determine whether the part icipant can then be followed per protocol 
scheduled study visits or whether additional follow-up visits should occur. 
Once CIC is initiated, the status of CIC use s hould be documented in the participant record at 
each visit (ie, use/nonuse). 
Cessation of Clean Intermittent Catheterization 
CIC should be discontinued when the following criteria are fulfilled: 
 the participant does not have any associated  symptoms which in the opi[INVESTIGATOR_885954] 
 the PVR is < 350 mL 
The date of discontinuation of CIC should be do cumented. If the investigator deems that CIC 
should not be discontinued even though the above criteria are fulfilled, then this should be 
documented and the reason given. Upon discontinuing CIC the participant will be seen for a 
follow-up visit 1 week later where the PVR, a ssociated symptoms, central laboratory urine 
04DEC2020 Abbreviated CSR 1839-201-021
59

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
analysis and culture/sensitivity will be reassessed. The investigator will determine whether the 
participant can then be followed at regularly sche duled study visits or wh ether additional follow-
up visits should occur based on PV R and/or associated symptoms. 
9.4.6. Bladder and Kidney Ultrasound 
Abdominal ultrasound of the bladder and kidneys will be performed with the bladder at least half 
full. Participants are excluded from this st udy if the screening ultrasound demonstrates the 
presence of bladder stones and/or intra-lumi nal filling defects of th e bladder suggestive of 
malignancy. In the case of unclear new findings identified at the exit visit ultrasound which may 
be suggestive of stones (kidney, ureter, or bladde r), other diagnostic measures must be performed 
in order to confirm the presence of stones, rule out bladder malignancy (eg, x-ray with or without contrast, urogram, CT scan, MRI or cystoscopy and histopathological confirmation). 
9.4.7. Concomitant Medications and Concurrent Procedures 
Concurrent procedures and concomitant medication (including name [CONTACT_2100], dose, route, 
and date) information will be collected at each st udy clinic and phone visit starting at the time of 
screening and ending at the part icipant Exit Visit. All concomitant medications and concurrent 
procedures must be recorded in the eCRF with a ll specific details associat ed with each use of the 
medication/procedure. 
9.5. Pharmacokinetics 
Pharmacokinetic parameters are not evaluated in this study. 
9.6. Pharmacodynamics 
Pharmacodynamic parameters are not evaluated in this study. 
9.7. Genetics 
Genetics are not evaluated in this study.  
9.8. Biomarkers 
Biomarkers are not evaluated in this study. 
04DEC2020 Abbreviated CSR 1839-201-021
60

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
10. Statistical Considerations 
10.1. Sample Size Determination 
For Stage 1, approximately 50 to70 participants will be enrolled to ensure that 10 to 20 
individuals are randomized in to each of the 4 cohorts (100 U Cohort: n = 10; 300 U Cohort: 
n = 20; 400 U Cohort: n = 20; 500 U Cohort: n = 20) to  provide sufficient data in the analysis 
and interpretation of safety results. Two particular adverse events of intere st are urinary retention 
and UTI. From previous BOTOX studies, the per centage of participant in the BOTOX-treated 
population experiencing these advers e events is 6% to 7% for ur inary retention and 20% to 30% 
for UTI. In cohort 1, the probability of obser ving at least one BOTOX-treated participant 
experiencing these adverse events is 0.[ADDRESS_1239411] one BOTOX-treated participant experiencing these 
adverse events is 0.63 to 0.69 a nd 0.97 to ~ 1, respectively.   
For Stage 2, 50 participants are required for each of the 4 BOTOX treatment groups and 
50 participants are required for the placebo group in order to obtain approximately 72% power to 
detect a between group difference of 1.[ADDRESS_1239412] 
deviation (SD) of 3.5 epi[INVESTIGATOR_49591] a 2-sided type  I error rate of 0.05. In order to account for 
participant attrition (estimated to be 5%), the sample size was increased to [ADDRESS_1239413] one occurrence of 
urinary retention or UTI in the BOTOX-tr eated population in Stage 2 is nearly 1. 
Table 10-1 Sample Size Assumptions for Stage 2 
Parameter Assumption/Estimate 
Primary endpoint Change from baseline to Week 12 in the number of epi[INVESTIGATOR_885955]/risk differencea 1.8 epi[INVESTIGATOR_885956] 3.5 epi[INVESTIGATOR_1841] 
α 0.05 
Sides 2 
Power 72% 
N per group  50 
Attrition rate 5% at Week 12 
N total 265 
N per group estimated 53 
a Based on previous BOTOX studies and relevant details 
 
Overall, a total of 315 to 335 randomized participants are re quired for the entire study. 
04DEC2020 Abbreviated CSR 1839-201-021
61

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
10.2. Populations for Analyses 
The analysis populations will consist of  participants as defined below: 
Table 10-2 Analysis Populations 
Population Definition Study Treatment 
Screened All screened participants who sign informed consent  
Enrolled All the participants who sign informed consent and screened with 
eligibility verified  
Intent-to-treat (ITT) For Stages [ADDRESS_1239414] efficacious dose. For Stage 1, the analyses of safety endpoints will take primacy; analysis of efficacy endpoints will be supplemental. For the prior reason, efficacy 
analyses for Stage 1 will be descriptive in natu re only; no inferential te sting will be performed.  
The statistical analysis plan (SAP) will be developed and finalized before database lock for stages 1 and 2, separately. SAP will describe the participant populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data.  
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints for Stage 2 
10.3.1. Key Statistical Methodology 
The methodologies defined below apply as specified to individual endpoints.   
Table 10-3 Statistical Methodology 
Methodology Description 
Categorical counts  Number of participants in individual categories 
o Participants with ≥ 1 qualifying event counted once per individual category 
Categorical descriptives  Number and percentage of participants in individual categories o Participants with ≥ 1 qualifying event counted once per individual category 
 N1 if percentage denominator ≠ number of participants in the population (standard 
04DEC2020 Abbreviated CSR 1839-201-021
62

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
Methodology Description 
percentage denominator) 
o N1 = participants with nonmissing baseline value 
PCS descriptives  Number and percentage of participants meeting potentially clinically significant (PCS) criteria 
o Participants with ≥ 1 qualifying event counted once per PCS category  
 Percentage denominator = number of participants with nonmissing baseline and 
≥ 1 nonmissing postbaseline assessment 
o Unevaluable assessments considered missing 
Event descriptives  Number and percentage of even ts in individual categories 
o Events counted individually for each instance 
 Percentage denominator = total number of events 
Shift analysis  Number and percentage of participants in individual baseline and postbaseline categories 
 Percentage denominator = number of participants in individual baseline categories 
 N1 = participants with nonmissing values at both baseline and the specified 
postbaseline analysis visit 
Continuous 
descriptives  N1, mean, SD, median, minimum, maximum 
 N1 = participants with nonmissing value 
CFB descriptives  Continuous descriptives for baseline, postbaseline, and change from baseline (CFB) 
values 
 N1 = participants with nonmissing values at baseline visit 
 Missing values replaced by [CONTACT_885983] (LOCF) 
CFB ANCOVA  Continuous descriptives and standard error (SE) for baseline, postbaseline, with LOCF,and CFB values 
 Estimates derived from mixed model for CFB value controlling for factors (treatment group and stratification variables) and covariates (baseline value) 
o Least squares (LS) means and standard errors 
o LS mean differences, standard erro rs, and 95% confidence intervals vs  placebo 
o P-values from contrast t-test comparing [BOTOX dose groups vs placebo] 
 N1 = participants with nonmissing values at baseline  
CFB ANCOVA Sensitivity  Continuous descriptives and standard error (SE) for baseline, postbaseline with only observed values, and CFB values 
 Estimates derived from mixed model for CFB value controlling for factors (treatment 
group and stratification variables) and covariates (baseline value) 
o Least squares (LS) means and standard errors 
o LS mean differences, standard errors, and 95% confidence intervals vs placebo 
 P-values from contrast t-test compar ing [BOTOX dose groups vs placebo] 
 N1 = participants with nonmissing values at both baseline and the specified postbaseline analysis visit 
04DEC2020 Abbreviated CSR 1839-201-021
63

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
Methodology Description 
Responder  Categorical descriptives for responders and nonresponders 
o Nonresponders include:  Participants who do not meet responder criteria 
 Participants with no postbaseline values  
 95% confidence interval for the proportion 
 Estimates derived from Cochran-Mantel-Haenszel (CMH) model controlling for stratification factors  o Mantel-Haenszel (MH) odds ratios (ORs) and confidence intervals vs  placebo 
o P-values for the adjusted odds ratio of BOTOX dose groups vs placebo 
 N1 = all participants unless otherwise specified 
Time-to-event  Categorical descriptives for participants with events and censoring o Censoring includes:  Participants who do not meet event criteria 
 Participants with no postbaseline values 
 Quartiles and 95% confidence intervals for median derived from Kaplan-Meier (KM) 
nonparametric model using log-log transformation of survival function 
 Estimates derived from log-rank model controlling for stratification factors  
o P-values comparing BOTOX dose groups vs placebo  
 N1 = all participants unless otherwise specified 
KM figure  Step-function figure of [survival function/cumulative distribution function  [1  survival function]] estimates with censoring indicators, derived from KM nonparametric model 
ANCOVA = analysis of covariance; ANOVA = analysis of variance; CFB = change from baseline; Cochran-Mantel-Haenszel; KM = Kaplan-Meier; LOCF = the last  observation carried forward; TTE = time-to-event. 
[IP_ADDRESS]. Hypothesis 
For the primary efficacy analysis, the null hypothesi s is that there is no difference between each 
BOTOX and Hydrogel admixture group and place bo and Hydrogel admixture group as measured 
by [CONTACT_885984][INVESTIGATOR_67661] 
[ADDRESS_1239415] bo and Hydrogel admixture group as measured 
by [CONTACT_885985][INVESTIGATOR_67661] 12.  
[IP_ADDRESS]. Methods of Analysis  
In general, baseline is defined as the last  nonmissing assessment before Day 1. Continuous 
variables will be summarized with descriptive statistics (sample size, mean, median, standard deviation, minimum, and maximum values). Ca tegorical variables will be summarized with 
frequency distributions (c ounts and percentages).  
04DEC2020 Abbreviated CSR 1839-201-021
64

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
10.3.2. Efficacy Analyses 
[IP_ADDRESS]. Collection and Derivation of Primary and Secondary Efficacy Measures 
Primary Measure (Number of urinary in continence epi[INVESTIGATOR_1841] [UIE] per day):  
UIE will be recorded in a 3-day bladder diary and calculated as the average number of epi[INVESTIGATOR_885957] a consecutive 3-day period. 
The participants baseline number of UIE will be the average from the 3 reported consecutive 
days immediately prior to randomization. 
Secondary Measures (Number of micturiti on epi[INVESTIGATOR_885958]):  Both secondary measures will be recorded by [CONTACT_885986]. Number of 
micturition epi[INVESTIGATOR_885959] a consecutive 3-day average. The 
volume voided per micturition will be calculated from the total urine volume from micturitions 
(toilet voids or catheterizations ) over one 24-hour period during the 3-day participant bladder 
diary divided by [CONTACT_885987] 24-hour period. 
Missing Data 
Every effort will be made to obtain required data at each scheduled evaluation from all 
participants who have been enrolled. The last observation carried forw ard (LOCF) imputation 
method will be used for the primary analysis in Stage 2. Sensitivity analyses will be performed 
using only observed data. 
[IP_ADDRESS]. Primary and Secondary Efficacy Analyses 
Primary Efficacy Variable  
The primary efficacy variable is the change in the average number of urinary incontinence (UIE) 
epi[INVESTIGATOR_885960]. The primary time point will be Week 12 after instillation.   
The primary variable will be calculated based on change from baseline of the consecutive 3-day 
average at each scheduled study visit. Calculatio n of averages will employ available data without 
imputation. If no data are available for the c onsecutive 3-day period, that average will be 
considered missing for that participant.  
Secondary Efficacy Variables 
The secondary efficacy variables are the cha nge from baseline for the average number of 
micturition epi[INVESTIGATOR_885961]. The primary timepoint 
will be Week 12 after instillation in Stage 2. 
04DEC2020 Abbreviated CSR 1839-201-021
65

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
The secondary variables will be calculated ba sed on change from baseline of the consecutive 
3-day average at each scheduled study visit. Calculation of averages wi ll employ available data 
without imputation. If no data are available for the consecutive 3-day period, that average will be 
considered missing for that participant. 
 
Endpoint Description Timing Methodology 
Endpoint 1 change in the average number of UIE at 
Week 12 from baseline with LOCF Weeks 1  24 CFB descriptives 
CFB ANCOVA  
Endpoint 2 change in the average number of UIE at Week 12 from baseline with observed 
values  Weeks 1- 24 CFB descriptives 
CFB ANCOVA 
Sensitivity 
Endpoint 3 change from baseline in the average 
number of micturition epi[INVESTIGATOR_885962] 12 Weeks 1  24 CFB descriptives 
CFB ANCOVA 
Endpoint 4 change from baseline in volume voided per 
micturition to Week 12 Weeks 1  24 CFB descriptives 
CFB ANCOVA 
ANCOVA = analysis of covariance; CFB = change from baseline; LOCF = th e last observation carried forward; 
UIE = urinary inco ntinence epi[INVESTIGATOR_1841]. 
[IP_ADDRESS]. Multiple Comparisons Procedure 
There will be no adjustments for multiple comparisons. 
04DEC2020 Abbreviated CSR 1839-201-021
66

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
10.3.4. Safety Analyses 
The following safety categories will be summarized as appropriate (eg, categorical or continuous 
descrip
tives, shift tables) for the safety population and will be fully defined in the SAPs. 
 Adverse events 
04DEC2020 Abbreviated CSR 1839-201-021
67

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
 Physical examination 
 Vital signs (pulse rate, blood pressure, and body temperature) 
 Urine dipstick reagent strip test 
 Urinalysis (with urine culture/sensitivity, as applicable) 
 Hematology and clinical chemistry 
 PVR urine volume 
 Kidney and bladder ultrasound 
 Urine pregnancy test for wome n of childbearing potential 
 Concomitant medications 
 Concurrent procedures 
Adverse events will be mapped to a Medical Di ctionary for Regulatory Activities (MedDRA) 
preferred term and system organ classificati on (SOC) using MedDRA. For each adverse event 
reported, the number and percent of participants  will be tabulated based on the preferred term. 
The tables will be generated by [CONTACT_885988]. 
10.3.6. Analyses Timepoints and Scope 
There will be a database lock for Stage 1 and 2 database locks for Stage 2: one for primary and 
one for final.  Stage [ADDRESS_1239416]-
randomization (or prematurely exited the study pr ior to Week 12). The final analysis will be 
performed on study completion. Details of the pr imary analyses and final analysis will be 
described in separate SAPs. 
The statistical analysis plans will desc ribe the analyses in greater detail. 
04DEC2020 Abbreviated CSR 1839-201-021
68

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
11. References 
Abrams P, Cardozo L, Fall M, Griffiths D, Rosi er P, Ulmsten U, et al. Standardisation Sub-
committee of the International Continence Society.  The standardisation of terminology of lower 
urinary tract function: report from the Standa rdisation Sub-committee of the International 
Continence Society. Neurourol Urodyn. 2002;21(2):167-178. 
Apostolidis A, Dasgupta P, Fowler CJ. Propos ed mechanism for the efficacy of injected 
botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49:644-650. 
Apostolidis A, Popat R, Yiangou Y, Cockayne D,  Ford AP, Davis JB, et al. Decreased sensory 
receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of 
botulinum toxin for human detrusor overactiv ity. J Urol. 2005;174:977-983; discussion 982-983. 
Chancellor MB, Yehoshua A, Waweru C, Globe D, Cheng IN, Campbell KL et al. Limitations of 
anticholinergic cycling in patients with overac tive bladder (OAB) with urinary incontinence 
(UI): results from the CONsequences of Treat ment Refractory Overactive bLadder (CONTROL) 
study. Int Urol Nephrol. 2016;48(7):10291036. 
Chancellor MB, Fowler CJ, Apostolidis A, de Groat WC, Smith CP, Somogyi GT, et al. Drug 
insight: biological effects of botulinum toxin A in  the lower urinary tract. Nat Clin Pract Urol. 
2008;5(6):319-28. 
Chapple CR, Sievert KD, MacDiarmid S, Khu llar V, Radziszewski P, Nardo C, et al. 
OnabotulinumtoxinA 100 U significantly improv es all idiopathic overactive bladder (OAB) 
symptoms and quality of life in patients with OAB and urinary incontinence: a randomized, 
double blind, placebo-controlled trial. Eur Urol. 2013 (Epub ahead of print). 
Chartier-Kastler EJ, Mongiat-Artus P, Bitker MO, Chancellor MB, Richard F, Denys P. Long-
term results of augmentation cystoplasty in spi[INVESTIGATOR_387800]. Spi[INVESTIGATOR_35406]. 
2000;38(8):490-4. 
Coelho A, Dinis P, Pi[INVESTIGATOR_1946] R, Gorgal T, Silva C, Silva A, et al. Distribu tion of the high-affinity 
binding site and intracellular targ et of botulinum toxin type A in the human bladder. Eur Urol. 
2010;57(5):884-90. Collins VM, Daly DM, Liaskos M, McKay NG, Sellers D, Chapple C, et al. 
OnabotulinumtoxinA significantly attenuates blad der afferent nerve firing and inhibits ATP 
release from the urothelium. BJU Int. 2013;112:10181026. 
Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of 
an overactive bladder symptom a nd health-related quality of life questionnaire: the OAB-q. Qual 
Life Res. 2002 Sep;11(6):563-574. 
04DEC2020 Abbreviated CSR 1839-201-021
69

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
Debruyne FM, Heesakkers JP. Clinical and soci oeconomic relevance of overactive bladder. 
Urology. 2004;63([ADDRESS_1239417] 1):42-44. 
Fowler CJ. Bladder afferents and their role in  the overactive bladder. Urology. 2002;59:37-42. 
Franks ME, Somogyi GT, Phelan MW, Fraser MO, Yokoyama T, Ghosh R, et al. Botulinum 
toxin injection into the bladder wall decrease s acetylcholine (Ach) and norepi[INVESTIGATOR_238] (NE) 
release; potential treatment fo r the overactive bladder. J Ur ol. 2000;163([ADDRESS_1239418]):42. Abstract 
no. 181. 
Giannantoni A, Di Stasi SM, Nardicchi V, Zucchi A, Macchioni L, Bini V, et al. Botulinum A 
toxin injections into the detrusor muscle decrea se nerve growth factor bladder tissue levels in 
patients with neurogenic detrusor ov eractivity. J Urol. 2006;175:2341-2344. 
Gormley EA, Lightner DJ, Faraday M, Vasavada  SP. Diagnosis and treatment of overactive 
bladder (non-neurogenic) in adults: AUA/SU FU Guideline Amendment. J Urology. 2015; 193, 
1572-1580. Herrero BA, Ecklung AE, Streett CS, Ford DF, Ki ng JK.  Experimental botulism in monkeys:  a 
clinical pathological study.  Exp Mol Pathol. 1967;6:84-95. 
Homma Y, Batista J, Bauer S, Griffiths D, Hilto n P, Kramer G, et al. Urodynamics. In: Abrams 
P, Cardozo L, Khoury S, Wein A, editors. Incont inence. Plymouth, [LOCATION_006]: Plymbridge Distributors 
Ltd.; 2002. p. 317-372. Janknegt RA, Hassouna MM, Siegel SW, Schmidt RA, Gajewski JB, Rivas DA, et al. Long-term 
effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol. 
2001;39(1):101-106. 
Krhut J, Navratilova M, Sykora R, Jurakova M, Gärt ner M, Mika D, et al. Intravesical instillation 
of onabotulinum toxin A embedded in inert hydroge l in the treatment of idiopathic overactive 
bladder: A double-blind randomized pi[INVESTIGATOR_39400]. Scand J Urol. 2016;50(3):200-205. Epub 2016 
Jan 12. Milsom I, Stewart W, Thuroff J. The prevalen ce of overactive bladder. Am J Manag Care. 2000; 
6([ADDRESS_1239419]):S565-S573. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. 
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary 
incontinence: results of a phase 3 random ized placebo-controlled trial. J Urol. 
2013;189(6):2186-2193. 
Nitti VW, Khullar V, Van Kerrebroeck P, Hers chorn S, Cambronero J, Angulo JC et al. 
Mirabegron for the treatment of overactive bladde r: a prespecified pooled efficacy analysis and 
04DEC2020 Abbreviated CSR 1839-201-021
70

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
pooled safety analysis of three randomized, double-blind, placebo-controll ed, phase III studies. 
Int J Clin Pract. 2013a;67(7):619632. 
Schulte-Baukloh H, Priefert J, Knispel HH, Lawrence GW. Miller K, Neuhaus J. Botulinum 
toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in 
children and adolescents who ha ve neurogenic detrusor overac tivity: a single-blind study. 
Urology. 2013;81(5):1052-1057. 
Scott AB.  Clostridial toxins as therapeutic agents.  In:  Simpson LL, editor.  Botulinum 
neurotoxin and tetanus toxin.  Ne w York, Academic Press. 1989;399-412. 
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams  P, Herzog AR, Corey R, et al. Prevalence 
and burden of overactive bladder in the [LOCATION_002]. Wo rld J Urol. 2003;20(6):327-336. 
Thuroff JW, Abrams P, Andersson KE, Artib ani W, Chapple CR, Drake MJ, et al. EAU 
guidelines on urinary incontinen ce. Eur Urol. 2011;59(3):387-400. 
Thiagamoorthy G, Cardozo L, Robinson D. Cu rrent and future pharmacotherapy for treating 
overactive bladder. Expert Opin Pharmacother. 2016 Jul;17(10):1317-1325. 
 
04DEC2020 Abbreviated CSR 1839-201-021
71

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
12. Appendices 
12.1. Appendix 1: Abbreviations and Trademarks 
Term/Abbreviation Definition 
AE adverse event 
ANCOVA analysis of covariance 
AUA American Urological Association 
BCI bladder contractility index 
BoNT/A botulinum toxin serotype A  
BOTOX Botulinum Toxin Type A Purified Neurotoxin Complex (US 
Adopted Name [CONTACT_687984]) 
CFB change from baseline 
CMH Cochran-Mantel-Haenszel 
CIC clean intermittent catheterization 
DMSO dimethyl sulfoxide  
DRC data review committee 
eCRF electronic case report form 
EAU European Association of Urology 
EDC electronic data capture  
FSV first sensation to void 
GCP Good Clinical Practices 
HED human equivalent dose 
HIPAA Health Insurance Portab ility and Accountability Act 
HRQL health-related quality of life  
Hydrogel Hydrogel refers to RTGel  
ICH International Conference on Harmonisation 
IDC involuntary detrusor contraction 
IEC Independent Ethics Committee 
IPIS Instillation Procedure Impression Scale 
ITT Intent-to-treat IRB Institutional Review Board 
IWRS interactive web response system 
KM Kaplan-Meier 
04DEC2020 Abbreviated CSR 1839-201-021
72

 
 
Approval Date :  
 20-Dec-2018CONFIDENTIAL Protocol 1839-201-021 Amendment 2 
BOTOXﬁ (Botulinum Toxin Type A)  
Purified Neurotoxin Complex 
 
 
LOCF last observation carried forward 
LS least squares 
MCC maximum cystometric capacity 
NDO neurogenic detrusor overactivity 
NOEL no observed effect level 
OAB overactive bladder 
PCS potentially clinically significant 
PPBC Patient Perception of Bladder Condition 
PSA prostate-specific antigen  
PVR Post-void residual 
Pdetmax maximum detrusor pressure 
SAE Serious adverse event 
SAP statistical analysis plan 
SD standard deviation 
SE standard error 
UDS urodynamic studies 
UIE urinary incontinence 
UTI urinary tract infection 
 
 
04DEC2020 Abbreviated CSR 1839-201-021
73
